Genentech : FDA Advisory Committee Reviews Columvi SBLA For DLBCL Treatment In Non-ASCT Candidates

An FDA advisory committee reviewed Genentech's Columvi combination therapy for relapsed or refractory diffuse large B-cell lymphoma, focusing on the applicability of the Phase III STARGLO trial results to the U.S. patient population. Committee members indicated that further data are needed, particularly regarding the multiregional clinical trial's patient demographics. The FDA's decision on approval for the Columvi combination is expected by July 20, 2025.

Analysis

Genentech, a subsidiary of the Roche Group (RHHBY), is pursuing a supplemental Biologics License Application (sBLA) for Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients ineligible for autologous stem cell transplant. A recent U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussion highlighted concerns regarding the applicability of the Phase III STARGLO trial results to the U.S. patient population, with committee members indicating a need for further data. The STARGLO study was a multiregional clinical trial involving 274 patients across 13 countries, with 52% enrolled outside Asia, which may be the basis for the committee's questions on U.S. representation. While ODAC recommendations are non-binding, this request for additional information introduces a potential hurdle and uncertainty to the approval timeline. The FDA's final decision on this Columvi combination is expected by July 20, 2025, a relatively distant date that, combined with the data request, aligns with the neutral to slightly negative sentiment (score -0.1 for RHHBY) associated with this development.

Key Decisions for Investors

• Investors in Roche (RHHBY) should closely monitor Genentech's forthcoming strategy and any subsequent data submissions aimed at addressing the FDA advisory committee's request for further information on Columvi, as this will be pivotal for the sBLA approval.
• The scheduled FDA decision date of July 20, 2025, signifies that any potential revenue impact from this expanded Columvi indication is not immediate and remains contingent upon overcoming current regulatory scrutiny.
• It is prudent to consider the risk of a delayed approval timeline or a more restricted label for Columvi in this DLBCL setting if the concerns regarding the STARGLO trial's applicability to the U.S. patient population are not adequately resolved.